Glufosfamide: Beta-D-Glc-IPM, D 19575

Drugs in R and D

Volumn 6, Issue 1, 2005, Pages 49-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADRIAMYCINONE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CYCLOPHOSPHAMIDE; GEMCITABINE; GLUCOSE; GLUFOSFAMIDE; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; MAFOSFAMIDE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BRAZIL; CANCER THERAPY; CANCER TISSUE; CHEMICAL BINDING; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DRUG RESEARCH; DRUG TARGETING; DRUG TRANSPORT; FATIGUE; FOOD AND DRUG ADMINISTRATION; GERMANY; GLUCOSE UTILIZATION; GLYCOSIDATION; GRANULOCYTOPENIA; GREECE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAXIMUM TOLERATED DOSE; METABOLIC ACIDOSIS; NAUSEA; NEPHROTOXICITY; NEURITIS; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; RENAL DIABETES; SKIN DISEASE; SOLID TUMOR; SOUTH AND CENTRAL AMERICA; THROMBOCYTOPENIA; TISSUE METABOLISM; UNITED KINGDOM; UNITED STATES; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; NEOPLASMS; PHOSPHORAMIDE MUSTARDS;

EID: 13844320743     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506010-00006     Document Type: Article

References (12)

1. Threshold Pharmaceuticals Inc. Threshold Pharmaceuticals Receives FDA Fast-Track Status for Glufosfamide. Media Release: 15 Nov 2004. Available from URL: http://www.thresholdpharm.com
2. Threshold Pharmaceuticals Inc. Threshold Pharmaceuticals Initiates Combined Phase 1/2 Trial Evaluating Glufosfamide as First-Line Pancreatic Cancer Therapy. Media Release: 20 Dec 2004. Available from URL: http://www.thresholdpharm.com
3. Pohl J, Bertram B, Hilgard P. D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemotherapy and Pharmacology 35: 364-370, Mar 1995
4. Stüben J, Port R, Bertram B. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H] -thymidine in various tissues of the rat. Cancer Chemotherapy and Pharmacology 38: 355-365, Aug 1996
5. Depenbrock H, Thödmann R, Kemmerich M, et al. Phase I clinical and pharmacokinetic evaluation of the new glucose-linked isophosphoramide mustard D-19575 administered every 21 days in patients with solid tumors. Onkologie 20 (Suppl. 1): 55, Oct 1997
6. Briasoulis E, Judson I, Pavlidis N, et al. A phase I trial of D19575, a beta-D-glucose-linked isophosphoramide mustard given as a 6-hour infusion. Annals of Oncology 9 (Suppl. 2): 123, 1998
7. Briasoulis EA, Pavlidis N, Droz J-P, et al. Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in advanced pancreatic cancer. 93rd Annual Meeting of the American Association for Cancer Research 43: 748-749, Mar 2002
8. Van Den Bent M, De Jonge M, Lesimple T, et al. Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in recurrent glioblastoma multiforme. 93rd Annual Meeting of the American Association for Cancer Research 43: 748, Mar 2002
9. Tidmarsh GF, Kudajbergenova IO, Navrusov SN, et al. An open label phase II trial of glufosfamide: a beta-d-glucose-linked isophosphoramide mustard given as 1 -hour infusion in patients with advanced breast cancer. 40th Annual Meeting of the American Society of Clinical Oncology: 38, Jun 2004
10. Threshold Pharmaceuticals. Threshold Pharmaceuticals to Present Data on Glufosfamide Trial Results at 2004 ASCO Annual Meeting. Media Release: 5 Jun 2004. Available from URL: http://www.thres-holdpharm.com
11. Sargent J, Bertram B, Pohl J. Effect of D-19575, a glucose derivative of ifosfamide, on fresh cells from haematological and solid tumours. British Journal of Cancer 73 (Suppl. XXVI): 31, Mar 1996
12. Seker H, Bertram B, Bürkle A, et al. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. British Journal of Cancer 82: 629-634, Feb 2000